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$Q(5*SHUVSHFWLYH´ 
 
Abstract 
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme) of pembrolizumab (Keytruda®) 
to submit evidence of its clinical and cost-effectiveness for the treatment of locally advanced or 
metastatic urothelial cancer where cisplatin is unsuitable. The School of Health and Related Research 
Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent 
Evidence Review Group (ERG). The ERG produced a detailed review of the evidence for the clinical 
and cost-HIIHFWLYHQHVVRIWKHWHFKQRORJ\EDVHGXSRQWKHFRPSDQ\¶VVXEPLVVLRQWR1,&(7KHFOLQLFDO
HIIHFWLYHQHVVHYLGHQFHLQWKHFRPSDQ\¶VVXEPLVVLRQfor pembrolizumab was based upon one Phase II, 
single-arm, open-label, non-randomised study (KEYNOTE-052). The evidence for the comparator 
(carboplatin plus gemcitabine) was based on four studies including one randomised controlled trial and 
three cohort studies. In the absence of head-to-head trials, the company conducted an indirect treatment 
comparison for both PFS and OS, by firstly adjusting cross-study differences using simulated treatment 
comparison approach and then synthesising the evidence based on an assumption of constant hazard 
ratios using a standard meta-analysis model and time-varying hazard ratios using fractional polynomial 
models. The treatment effect of pembrolizumab was more favourable in the adjusted population 
compared with the observed effect in the KEYNOTE-052 study. The company submitted a de novo 
partitioned survival cohort simulation model, which partitions the OS time into PFS and post-
progression survival. The probabilistic incremental cost-effectiveness ratio (ICER) for pembrolizumab 
compared with carboplatin plus gemcitabine was estimated to be £37,081 per quality-adjusted life year 
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(QALY) gained, based upon the results within the FRPSDQ\¶V health economic model. Following a 
critique of the model, for their preferred base case the ERG corrected some minor model errors, chose 
a progression approach for estimating utilities, and revised the extrapolation of PFS and OS. The ERG¶s 
probabilistic base case ICER was estimated to be £67,068 per QALY gained. The ERG also undertook 
a range of exploratory sensitivity analyses which suggested that the ICER was highly uncertain. In 
particular, the choices of extrapolation for the OS of pembrolizumab and the stopping rule for 
pembrolizumab had the largest impacts upon the ICER. The NICE appraisal committee recommended 
pembrolizumab for use within the Cancer Drugs Fund as an option for treating locally advanced or 
metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, provided 
that pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses 
and the conditions of the managed access agreement for pembrolizumab are followed.  
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Key points for decision makers 
x Pembrolizumab is an effective treatment option for locally advanced or metastatic urothelial 
cancer where cisplatin is unsuitable, although the relative treatment efficacy is uncertain due to 
paucity of evidence. 
x The choices of extrapolation for the overall survival of pembrolizumab and the stopping rule 
for pembrolizumab had the largest impacts upon the cost-effectiveness estimates, with the 
Evidence Review Group estimated cost per quality-adjusted life year gained ranging from 
£48,330 to £136,971 under plausible assumptions. 
x Pembrolizumab was recommended for use within the Cancer Drugs Fund as an option for 
untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-
containing chemotherapy is unsuitable, only if pembrolizumab is stopped at 2 years of 
uninterrupted treatment or earlier if the disease progresses and the conditions of the managed 
access agreement for pembrolizumab are followed. 
 
 
1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation 
responsible for providing national guidance on promoting good health and preventing and treating ill 
health in priority areas with significant impact. Health technologies must be shown to be clinically 
effective and to represent a cost-effective use of National Health Service (NHS) resources in order for 
NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal 
(STA) process usually covers new single health technologies within a single indication, soon after their 
UK market authorisation.[1] Within the STA process, the company provides NICE with a written 
VXEPLVVLRQ WKDW VXPPDULVHV WKH FRPSDQ\¶V HVWLPDWHV RI WKH FOLQLFDO DQG FRVW HIIHFWLYHQHVV RI WKH
technology, alongside the implemented mathematical model. This submission is reviewed by an 
external organisation independent of NICE (the Evidence Review Group [ERG]), which consults with 
FOLQLFDOVSHFLDOLVWVDQGSURGXFHVDUHSRUW$IWHUFRQVLGHUDWLRQRIWKHFRPSDQ\¶VVXEPLVVLRQWKH(5*
report and testimony from experts and other stakeholders, the NICE Appraisal Committee (AC) 
formulates preliminary guidance, the Appraisal Consultation Document (ACD), which indicates the 
initial decision of the AC regarding the recommendation (or not) of the technology. Stakeholders are 
then invited to comment on the submitted evidence and the ACD, after which a further ACD may be 
produced or a Final Appraisal Determination (FAD) issued, which is open to appeal. In this STA, NICE 
directly produced a FAD having considered the probability of an appeal. 
This paper presents a summary of the ERG report [2] for the STA of  pembrolizumab for untreated 
locally advanced or metastatic urothelial cancer when cisplatin is unsuitable. A brief summary of the 
4 
 
resulting NICE guidance for the use of this technology in England is also provided. Full details of all 
relevant appraisal documents (including the appraisal scope, ERG report, company and consultee 
submissions, FAD and comments from consultees) can be found on the NICE website.[3]  
2. The Decision Problem 
Urothelial cancer may arise from the transitional cells in the endothelium of the bladder, renal pelvis, 
ureter, and urethra. In the UK, urothelial cancer accounts for approximately 90% bladder, renal pelvis, 
ureter and urethra cancers,[4] and bladder cancer is recognised as the 10th most common form of cancer, 
and the 7th most common cause of cancer mortality.[5] Bladder cancer is most frequent within an elderly 
population; in the UK 55% of bladder cancer is diagnosed in people aged 75 years and over (Cancer 
Research UK 2012 to 2014).[6] The survival in untreated bladder cancer patients is uncertain and 
survival data for patients with urothelial cancer are not available because of the scarcity of such data in 
the literature. However, it is known that survival rates for patients with bladder cancer are strongly 
correlated to disease stage at diagnosis. For patients with stage IV disease, the likelihood of survival is 
35% and 28% at 1 year for men and women, respectively, and 9% and 11% at 5 years following initial 
diagnosis. There is variation in 5-year overall survival for patients with advanced or metastatic 
urothelial cancer, and the lowest 5-year survival rates suggested in the literature were 6% globally.[7] 
2.1 Current Treatment 
In the UK the current first line treatment for patients with locally advanced or metastatic urothelial 
carcinoma who are cisplatin ineligible is carboplatin in combination with gemcitabine.[8] Some patients 
may alternatively receive best supportive care (BSC). Atezolizumab has a marketing authorisation for 
untreated locally advanced or metastatic urothelial carcinoma when cisplatin is unsuitable. However, 
because of substantial uncertainty in the clinical effectiveness evidence, NICE recommended 
atezolizumab for use within the Cancer Drugs Fund only [9] and hence atezolizumab was not considered 
to be standard practice for the purpose of this appraisal. 
Pembrolizumab (Keytruda®) is a monoclonal antibody of the IgG4/kappa isotype designed to exert 
dual ligand blockade of the PD-1 pathway by directly blocking the interaction between PD-1 and its 
ligands, PD-L1 and PD-L2 which appear on antigen-presenting or tumour cells. Pembrolizumab as a 
monotherapy is licenced for the treatment of locally advanced or metastatic urothelial carcinoma in 
adults who are not eligible for cisplatin-containing chemotherapy. It is given by intravenous infusion at 
a fixed dose of 200mg every three weeks. Treatment should be continued until disease progression or 
unacceptable toxicity.[10] The original anticipated NHS list price was £2,630 per 100 mg vial.[3] The 
company has a commercial arrangement, which makes pembrolizumab available to the NHS with a 
discount. Unless otherwise stated, all results presented here used the discount. 
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3. The Independent ERG Review 
The company provided a submission to NICE on the clinical effectiveness and cost effectiveness of 
pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.[3] 
This submission was critically appraised by the ERG. In addition, the ERG identified areas requiring 
clarification, for which the company provided additional evidence prior to completion of the ERG 
report.[3] 
3.1 Clinical Evidence Provided by the Company 
The FRPSDQ\¶VVXEPLVVLRQCS) included a systematic review of the clinical effectiveness evidence. 
The KEYNOTE-052 study provided the main supporting clinical effectiveness evidence for this 
submission and is a Phase II, single-arm, open-label, non-randomised study.[11] KEYNOTE-052 was 
designed to test the efficacy and safety of pembrolizumab in patients with advanced/unresectable or 
metastatic urothelial cancer where cisplatin is unsuitable. The KEYNOTE-052 study is ongoing, and 
different data cut-off points are used in the CS [3] (9th March 2017), and Balar et al. (2017) [11] and 
the European Public Assessment Report (EPAR) [10]  (both 1st Sept 2016). 
The CS stated that KEYNOTE-052 was conducted in 16 countries, and 370 patients received at least 
one dose of pembrolizumab. The study population was predominantly male (77.3%) and white (88.6%) 
with 78.1% of the patients having an ECOG status of 1 (36.2%) or 2 (41.9%). The median age of study 
participants was 74 years (range 34-94 years). With regard to metastases location, 51 patients (13.8%) 
had lymph node only disease, while 315 patients (85.1%) had visceral disease and four patients (1.1%) 
had metastases location not reported. Pembrolizumab was administered in an un-blinded manner at a 
dosage of 200mg via intravenous infusion over 30 minutes every 3 weeks. Pembrolizumab treatment 
could continue for 24 months.  
The primary outcome of the KEYNOTE-052 study was objective response rate (ORR) with overall 
survival (OS) and progression-free survival (PFS) being secondary endpoints. At the data cut-off point 
of 9th March 2017, median OS was 11.0 months (95% confidence interval (CI): 10.0-13.6 months) and 
there were 188 deaths. Median PFS was 2.3 months (95% CI: 2.1-3.4 months) and ORR was 29.2% 
(95% CI: 24.6%-34.1%). 
All participants were monitored for adverse events (AEs) for 30 days following the end of treatment 
(this was 90 days for serious adverse event (SAE) monitoring, unless the participant initiated a new 
treatment, in which case it was 30 days after the end of treatment). At the data cut-off point of 9th March 
2017, patients had spent a median of 3.40 months (range 0.03-22.01 months) on treatment with 
pembrolizumab, with a mean of 8.20 months (standard deviation 6.84). The number of study medication 
administrations had median 5.00 doses (range 1.00-33.00 doses). Incidence of any adverse event (AE) 
was reported in the CS as being 97.6%, and incidence of treatment-related AEs was reported in the CS 
6 
 
as being 65.7%. The most common AEs were reported in the CS as being fatigue (33%), decreased 
appetite (24.1%), constipation (22.4%), urinary tract infection (21.6%), haematuria (15.7%) and an 
increase in blood creatinine (13.8%). The most common treatment-related AEs were reported in the CS 
as being fatigue (18.1%) and pruritus (16.8%). The CS reported 20 (5.4%) cases of mortality from AEs. 
In the absence of head-to-head evidence, the company conducted an indirect treatment comparison 
(ITC) for both PFS and OS, by firstly adjusting cross-study differences using a simulated treatment 
comparison (STC) approach [12] and then synthesising the evidence based on an assumption of constant 
hazard ratios using a standard meta-analysis model and time-varying hazard ratios using fractional 
polynomial models. Four studies of carboplatin plus gemcitabine were presented in the CS, including 
one randomised controlled trial [13] and three cohort studies.[14-16] There was considerable 
heterogeneity between the comparator studies with regard to patients and dosage and administration of 
gemcitabine and carboplatin. Median OS ranged from 7.2 months (95% CI: 5.9-8.5 months) to 10 
months (95% CI: not reported (NR)). PFS ranged from 4.4 months (95% CI: 1.03-7.75 months) to 5.8 
months (95% CI: NR). 
 
The STC approach included four prognostic factors: (&2* ; renal failure; presence of liver 
metastases or visceral metastases, and primary tumour site (upper or lower). The absolute treatment 
effect of pembrolizumab was more favourable in the adjusted population compared with the observed 
effect in the KEYNOTE-052 study.  
 
The second order fractional polynomial model with power p1=p2=0 was chosen as the best fitting model 
for obtaining the relative effect for OS and PFS in the original submission. In response to clarification, 
additional analyses were performed by the company with negative values for p1 and p2. The overall 
best fitting model was p1=p2=-2, which provided less favourable results for pembrolizumab when 
compared with the chosen best fitting model in the original submission. 
3.1.1 Critique of the Clinical Evidence and Interpretation 
The systematic review presented in the CS appears to be comprehensive. The ERG was confident that 
all relevant pembrolizumab studies for this patient population were included in spite of limitations with 
the search methodology used by the company. The specified inclusion and exclusion criteria did not 
generally reflect the decision problem specified in the NICE final scope. Studies of BSC and 
atezolizumab, both included as comparators in the NICE final scope, were not included in the 
submission. The ERG agreed that BSC should be excluded due to a paucity of evidence, and 
atezolizumab should be excluded as evidence for atezolizumab was too uncertain to enable a useful 
comparison. The quality assessment tools used to appraise the included studies were considered 
appropriate by the ERG. 
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The ERG was confident that the CS contained the only known study of pembrolizumab in the relevant 
patient population, KEYNOTE-052. As this study is open-label, it is susceptible to bias. KEYNOTE-
052 is an ongoing study and the data presented in the CS were immature. The ERG noted that the 
subgroup analyses presented in the CS should be treated with caution because PD-L1 expression is not 
a reliable predictor of outcomes in the urothelial cancer population. 
The ERG had coQFHUQVWKDWWKHFRPSDQ\¶VSRSXODWLRQDGMXVWPHQWDSSURDFKWREDODQFHWKHFURVV-study 
differences between KEYNOTE-052 and carboplatin plus gemcitabine studies lacked validity. The 
FRPSDQ\¶V DGMXVWPHQWV VXJJHVWed that patients in KEYNOTE-052 were less fit compared with the 
patients in each of the carboplatin plus gemcitabine studies. However, this was not supported by the 
reported summary of patient baseline characteristics from WKH LQFOXGHG VWXGLHV7KH (5*¶V FOLnical 
advisors also confirmed that patients in KEYNOTE-052 were not more frail compared with the patients 
in the comparator studies. The ERG noted that there was no evidence by subgroup for the comparator; 
hence it was not appropriate to conduct the ITC for the subgroups. 
3.2 Cost-Effectiveness Evidence Provided by the Company 
The company submitted a de novo partitioned survival cohort simulation model, which included three 
states: (i) progression-free; (ii) progressed disease and (iii) death. The model adopted a weekly cycle 
length and a 20-year time horizon. The incremental health gains, costs and cost-effectiveness of 
pembrolizumab were evaluated from the perspective of the UK NHS and Personal Social Services 
(PSS). To estimate the long-term OS and PFS for the pembrolizumab group, data from the KEYNOTE-
052 study were extrapolated using a piecewise approach with parametric distributions (i.e. a hybrid 
Kaplan-Meier (KM) approach). The company used the KM data up until 32 weeks and fitted a log 
normal distribution to the KM data from 32 weeks onwards as the base case for OS. The base case for 
PFS used KM data up until 9 weeks and fitted a Weibull distribution to the KM data from 9 weeks 
onwards. The fractional polynomial model with p1=p2=0 for OS and PS was used to estimate the 
relative treatment effect (i.e. time-varying hazard ratios) of pembrolizumab versus carboplatin plus 
gemcitabine. The PFS and OS for the carboplatin plus gemcitabine arm were modelled by applying the 
time-varying hazard ratios to the extrapolated PFS and OS of pembrolizumab arm, respectively.  
The estimated PFS for carboplatin plus gemcitabine was used as a proxy for time on treatment, and 
patients were assumed to receive no more than 6 cycles. Time on treatment data from the KEYNOTE-
052 study were extrapolated using standard parametric distributions to estimate time on pembrolizumab 
(a Gompertz distribution was used in the base case), and patients could receive a maximum of 24 months 
treatment in the model. In addition to the drug acquisition costs for pembrolizumab, carboplatin and 
gemcitabine, the model included costs for drug administration, subsequent treatment (a taxane or BSC, 
based on the latest UK market share estimates), disease management, end of life care and costs 
associated with treating adverse events.  All costs are based on published sources and were valued at 
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2015/16 prices. Health-related quality of life data from the KEYNOTE-052 trial were used within the 
model (see Table 1). The company estimated the utility values in two different ways: (i) based on 
SDWLHQWV¶GLVHDVHVWDWHVRWKDWSDWLHQWVKDGDGLIIHUHQWXWLOLW\LQWKHSURJUHVVLRQ-free health state and the 
progressed disease health state; and (ii) based on patients¶WLPHWRGHDWK. The latter was used within the 
FRPSDQ\¶V base case. All costs and health outcomes are discounted at a rate of 3.5% per annum.  
[Table 1 about here] 
The probabilistic incremental cost-effectiveness ratio (ICER) for pembrolizumab compared with 
carboplatin plus gemcitabine was estimated to be £37,081 per quality-adjusted life year (QALY) gained, 
based upon the results within the FRPSDQ\¶V health economic model. The CS argued that 
pembrolizumab satisfied 1,&(¶VFULWHULa for life-extending therapies at the end of life. 
3.2.1 Critique of the Cost-Effectiveness Evidence and Interpretation 
7KHFRPSDQ\¶VKHDOWKHFRQRPLFPRGHOVWUXFWXUHwas generally appropriate for the decision problem 
defined in the NICE final scope, though it should be noted that the only comparator tested within the 
economic evaluation was carboplatin plus gemcitabine. This was because there was no evidence for 
BSC and the evidence for atezolizumab was too uncertain to enable a useful comparison. The model 
was generally well described within the report. However, the STC lacked validity and there was 
substantial uncertainty around the extrapolation of the survival curves. The company undertook limited 
analyses to assess the impact of this uncertainty upon the model results, leading to an underestimate in 
the uncertainty around the ICER. 
3.3 Additional Work Undertaken by the ERG 
3.3.1 7KH(5*¶VVXJJHVWHGEDVHFDVH 
1) Correction of model errors 
The ERG had identified model errors relating to the way in which utilities were estimated and 
implemented and a model error around the proportion of males and females for estimating other-cause 
PRUWDOLW\LQWKHPRGHO7KHVHHUURUVKDYHEHHQDPHQGHGZLWKLQWKH(5*¶VSUHIHUUHGEDVHFDVHDQDO\VLV
although they did not impact upon the model results substantially. 
 
2) Utility by progression status 
The ERG preferred utility by progression status rather than by time to death within the base case, since 
the estimated utilities via the latter method were implausibly high for this patient group. This analysis 
substantially reduced the QALYs associated with pembrolizumab, hence the ICER associated with 
pembrolizumab compared with carboplatin plus gemcitabine increased to £42,588 per QALY gained. 
 
3) Extrapolation of OS and PFS using unadjusted data 
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The ERG had concerns about the validity of the STC undertaken by the company. Given that we did 
not have the individual patient-level data (IPD) to undertake our own population adjustment analyses, 
the ERG used a naïve indirect comparison based on the carboplatin plus gemcitabine arm from De 
Santis (2012) [13] and KEYNOTE-052. The reason to only include De Santis (2012) [13] for the 
comparator was because the ERG believed that it may not be appropriate to synthesise the evidence 
from the four carboplatin plus gemcitabine studies due to the heterogeneity with regard to patients and 
dosage and administration of gemcitabine and carboplatin; and De Santis (2012) [13] was the largest 
and most rigorously conducted study in the population of interest. The ERG noted that the naïve indirect 
comparison did not adjust for bias due to cross-study differences. The bias due to imbalance in the 
observables may be minimal in this case because De Santis (2012) [13] and KEYNOTE-052 had similar 
patient baseline characteristic distributions. The results of the naïve indirect comparison should be 
interpreted with caution as it did not account for residual bias.    
 
For carboplatin plus gemcitabine, only the OS KM curve was reported in the published paper. The ERG 
obtained the PFS KM curve from the first author of the paper. The ERG reconstructed IPD from these 
KM curves and the observed pembrolizumab data in KEYNOTE-052 for both OS and PFS using the 
algorithm proposed by Guyot et al. (2012).[17]  These curves were extrapolated using standard 
parametric distributions including exponential, Weibull, log logistic, log normal, Gompertz, gamma 
and generalised gamma and natural cubic spline models by Royston and Parmar (2002) [18] with 
knots={1, 2, 3} based on modelling the log of the cumulative hazard function. Based on assessing both 
LQWHUQDO DQG H[WHUQDO YDOLGLW\ WKH (5*¶V SUHIHUUHG PRGHO FKRLFHV IRU SHPEUROL]XPDE 26 was log 
normal; pembrolizumab PFS was spline with knots=3; carboplatin plus gemcitabine OS was spline with 
knots=2; and carboplatin plus gemcitabine PFS was spline with knots=3. 
 
This showed that using an unadjusted analysis resulted in an increase in life years and QALYs 
associated with carboplatin and gemcitabine and a decrease in life years and QALYs associated with 
pembrolizumab, compared with the adjusted analysis undertaken by the company. This led to a higher 
estimated ICER associated with pembrolizumab compared with carboplatin plus gemcitabine of 
£63,742 per QALY gained. 
 
4) Stopping rule/effectiveness of pembrolizumab after 24 months 
Given that a 2-year stopping rule has also been used within other indications, and this was how the 
company suggested pembrolizumab would be used, the ERG had used this stopping rule in their base 
case. However, the ERG did not agree that it was reasonable to discontinue the acquisition cost of 
pembrolizumab at 24 months within the model, whilst making use of the extrapolated PFS and OS from 
the study where patients did not discontinue treatment, as this was highly likely to overestimate the 
benefits of the treatment. Within their base case, the ERG had discontinued the acquisition cost of 
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pembrolizumab at 24 months, whilst using the hazard for carboplatin and gemcitabine within the 
pembrolizumab group beyond 24 months. Alternative assumptions were WHVWHG ZLWKLQ WKH (5*¶V
scenario analyses. As the hazards for the pembrolizumab survival curves were similar to those for the 
carboplatin plus gemcitabine survival curves beyond 24 months, this analysis did not impact upon the 
model results substantially. 
3.3.2 7KH(5*¶VVHQVLWLYLW\DQDO\VLV 
The ERG had re-run the deterministic univariate sensitivity analyses undertaken by the company using 
the new ERG base case. This suggested that the parameters varied by the company in their univariate 
sensitivity analysis did QRWLPSDFWXSRQWKH(5*¶VPRGHOUHVXOWVVXEVWDQWLDOO\ZLWKWKHZHHNO\FRVWLQ
the progression-free state following pembrolizumab treatment having the largest impact upon the model 
results. This analysis resulted in ICERs for pembrolizumab versus carboplatin plus gemcitabine in the 
range £61,647 to £67,019 per QALY gained.   
The ERG had also undertaken some additional sensitivity analyses which were not undertaken by the 
company, to assess plausible alternative assumptions. These analyses showed that the ICER was highly 
uncertain. In particular, the choices of extrapolation for the OS of pembrolizumab and the stopping rule 
for pembrolizumab had the largest impacts upon the ICER. There were four alternative curves that the 
ERG tested (three spline models and generalised gamma) which provided a good statistical fit (based 
on the Akaike information criterion (AIC) and Bayesian information criterion (BIC)) and visual fit to 
the pembrolizumab OS data, and for which our clinicians suggested all could be clinically plausible 
since long-term survival was unknown. These resulted in ICERs for pembrolizumab versus carboplatin 
plus gemcitabine ranging from £48,330 to £97,140 per QALY gained. Using the log normal distribution 
for pembrolizumab OS, as in the ERG base case, and assuming no stopping rule for pembrolizumab, 
increased the ICER to £84,905 or £136,971 per QALY gained, dependent upon the time on treatment 
curve extrapolation assumptions. Whilst lowering the cost of carboplatin did not substantially impact 
upon the model results, it should be noted that the direction of effect is to increase the ICER.  
3.4 Conclusions of the ERG Report 
The systematic review presented in the CS appears to be comprehensive. The health economic model 
submitted by the company was generally well described and justified. Due to the lack of head-to-head 
studies, the relative treatment effect of pembrolizumab was uncertain. The ERG believed that the 
FRPSDQ\¶VSTC lacked validity, and because of this the benefits of pembrolizumab were likely to be 
RYHUHVWLPDWHGZLWKLQ WKHFRPSDQ\¶VKHDOWKHFRQRPLFPRGHO7KHUH was also substantial uncertainty 
around the extrapolation of the survival curves. In addition, it was unclear whether a treatment stopping 
rule would be applied in practice, and if so it was unknown what impact this would have upon treatment 
effectiveness. These structural uncertainties were insufficiently explored by the company within their 
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scenario analyses, and hence the full range of plausible ICERs given the available evidence was not 
presented by the company.  
The ERG¶s probabilistic base case ICER was £67,068 per QALY gained. The scenario analyses run by 
the ERG suggested that the ICER was highly uncertain. In particular, the choices of extrapolation for 
the OS of pembrolizumab and the stopping rule for pembrolizumab had the largest impacts upon the 
ICER, with a cost per QALY gained for pembrolizumab versus carboplatin plus gemcitabine ranging 
from £48,330 to £136,971 per QALY gained under plausible assumptions. Pembrolizumab did appear 
WRVDWLVI\1,&(¶Vend of life criteria. 
4. Key Methodological Issues 
The key methodological issues in the evidence base were the ITC analysis and the use of a stopping 
rule for pembrolizumab at 24 months of treatment. STC is one of the population adjustment methods 
that could be used to balance the cross-study differences when performing an ITC analysis. However, 
the method is not without limitations.[12] TKHFRPSDQ\¶V,7&DQDO\VLVODFNHGYDOLGLW\DVWKHadjusted 
results suggested that patients in KEYNOTE-052 were less fit compared with the patients in each of 
the carboplatin plus gemcitabine studies, which was not supported by the reported summary of patient 
baseline characteristics from the included studies. Given that the ERG did not have access to the IPD 
in order to undertake their own ITC analysis to provide more valid estimates and given that in the largest 
RCT (De Santis (2012) [13]) the baseline characteristics were similar to KEYNOTE-052, the ERG 
preferred base case used analysis naïve indirect comparison using KEYNOTE-052 and De Santis (2012) 
[13] within the health economic model.    
The company suggested the use of a stopping rule for pembrolizumab at 24 months of treatment, and 
this is the protocol for the KEYNOTE study. However, there is no mention of a stopping rule in the 
Summary of Product Characteristics (SmPC) for pembrolizumab. The clinical advisors to the ERG 
suggested that there is uncertainty about whether a stopping rule would be implemented in clinical 
practice. Moreover, no patients were followed up beyond 24 months within the KEYNOTE study at the 
data cut-off point (9th March 2017) and hence there was no evidence about the impact of a stopping rule 
upon treatment effectiveness.  
The company also assumed that there were no costs of pembrolizumab beyond 24 months, whilst the 
effectiveness was extrapolated based on the trial evidence where patients did not discontinue treatment. 
The ERG believed that this was highly likely to underestimate the cost-effectiveness of pembrolizumab. 
Within their base case, the ERG discontinued the acquisition cost of pembrolizumab at 24 months, 
whilst using the hazard for carboplatin and gemcitabine within the pembrolizumab group beyond 24 
months, although other scenarios were also tested due to the uncertainty around this.  
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5. National Institute for Health and Care Excellence Guidance  
In June 2018, on the basis of the evidence available (including verbal testimony of invited clinical 
experts and patient representatives), the Appraisal Committee (AC) published guidance that 
pembrolizumab can be used within the Cancer Drugs Fund as an option for untreated locally advanced 
or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable. This 
recommendation was conditional on pembrolizumab being stopped at 2 years of uninterrupted treatment 
or earlier if the disease progresses and the conditions of the managed access agreement for 
pembrolizumab are followed. 
5.1 Consideration of Clinical and Cost-Effectiveness Issues Included in the Final Appraisal 
Determination (FAD) 
This section summarises the key issues considered by the Appraisal Committee. The full list of the 
issues considered by the AC can be found in the FAD.[3]  
5.1.1 Uncertainties in the Clinical Evidence 
The AC was concerned that in the absence of head-to-head trials comparing pembrolizumab with other 
WUHDWPHQWV LWZDVGLIILFXOW WRDVVHVVSHPEUROL]XPDE¶VUHODWLYH WUHDWPHQWEHQHILW The trial data were 
immature so there is considerable uncertainty about the long-term benefits. The AC concluded that 
pembrolizumab appeared to be an effective treatment option for people with untreated disease when 
cisplatin is unsuitable. However, there was considerable uncertainty about the size of the clinical benefit 
compared with other treatments and the duration of these benefits. 
The AC concluded that the results of the STC lacked validity and because of the limitations in the STC 
and in the evidence networks, the network meta-analyses were unlikely to provide a robust estimate of 
relative effectiveness. 
5.1.2 Uncertainties in the Economic Modelling  
The AC recognised that the extrapolation of OS was highly uncertain, and had a substantial effect on 
cost effectiveness. It concluded thDWDOWKRXJKWKH(5*¶VDSSURDFKSURGXFHGPRUHSODXVLEOHHVWLPDWHV
for the comparator arm, it was based on an unadjusted comparison. Therefore the AC considered both 
WKHFRPSDQ\¶VDQGWKH(5*¶VDSSroaches in its decision-making. 
The AC was concerned that the utility values based on time to death performed by the company results 
in higher utility values for people living longer than 180 days than the average value for PFS from the 
trial, and considered that it was more appropriate to use the progression state based utility values.  
6. $SSUDLVDO&RPPLWWHH¶V.H\Conclusion 
The AC concluded that pembrolizumab appears to be effective in a single-arm clinical trial 
(KEYNOTE-052), but it is difficult to establish the relative treatment effect because of the lack of head-
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to-head trials comparing with other treatments. The long-term benefits of pembrolizumab are uncertain 
because the trial is ongoing and this leads to uncertain estimate of cost effectiveness. The AC concluded 
that the most likely ICER for pembrolizumab compared with carboplatin plus gemcitabine was in the 
range from £43,702 to £65,642 per QALY gained, but could be higher. The AC agreed that 
pembrolizumab met the criteria to be considered as a life-extending end of life treatment, and longer 
follow-up data from KEYNOTE-052 and data from KEYNOTE-361, which directly compares 
pembrolizumab with other treatment, would help to address some of the uncertainties in the treatment 
effects. The AC therefore recommended pembrolizumab for the use within the Cancer Drugs Fund 
while further data are collected. 
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